MULTIPLE MYELOMA

During a Targeted Oncology Case-Based Roundtable event, Sikander Ailawadhi, MD, discussed maintenance therapy for patients with multiple myeloma.

Various frontline treatments can be administered to a patient with newly-diagnosed multiple myeloma. Rafael Fonseca, MD, and a group of peers compare the available agents during a Targeted Oncology, Cased- Based Roundtable event.

David H. Vesole, MD, PhD, discussed triplet regimens used for the treatment of transplant ineligible multiple myeloma during a Targeted Oncology Case-Based Roundtable event.

David Dingli, MD, PhD, professor of Medicine at the Mayo Clinic, discussed the treatment options available for patients with transplant-eligible multiple myeloma with a group of peers during a Targeted Oncology Case-Based Roundtable event.

Melflufen flufenamide has been deemed non-inferior to pomalidomide for the treatment of relapsed/refractory (R/R) multiple myeloma.

Joseph Mikhael, MD, explained the prognostic factors for consideration when treating newly-diagnosed multiple myeloma.

Noa Biran, MD, moderated a Targeted Oncology Case-Based Roundtable event during which time experts discussed treatment rationale in multiple myeloma.

In an interview with Targeted Oncology, Bishop, discussed how CAR T cells have reshaped the treatment landscape, the future of their use, and their potential in solid tumors.

During a Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.

In patients with multiple myeloma, the combination of motixafortide and granulocyte colony-stimulating factor achieved a 4.9-fold increase in hematopoietic stem-cell mobilization, and prepared most patients for autologous stem cell transplant, meeting both the primary and main secondary endpoints of the GENESIS Study.

Nicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.

Melissa Alsina, MD, reviewed the treatment options for transplant-eligible multiple myeloma based on the case of a 52-year-old male patient.

Multiple myeloma expert, Dr Clifton Mo, shares his insights on future directions for the treatment of multiple myeloma.

An expert hematologist-oncologist provides his perspective on the importance of managing toxicities in patients with relapsed/refractory multiple myeloma.

Clifton C. Mo, MD, reviews the ongoing multicenter phase 1 STOMP trial in relapsed/refractory multiple myeloma.

An expert hematologist-oncologist reviews the randomized, phase 3 BOSTON trial of a selinexor-based triplet regimen for the treatment of multiple myeloma.

Dr Clifton Mo describes second-line treatment options for the management of multiple myeloma, and treatment approaches for IMiD- and anti-CD38–refractory MM.

An expert hematologist-oncologist reviews the standard of care for transplant-eligible and transplant-ineligible patients with newly diagnosed MM and explores the role of quadruplet induction regimens.

Clifton C. Mo, MD, presents the case of a 79-year-old woman with R-ISS stage I multiple myeloma and shares his initial impressions.

Clifton C. Mo, MD, provides insight on the management of multiple myeloma and evaluates the role of current treatment regimens.

During a Targeted Oncology Case-Based Roundtable event, Joseph Mikhael, MD, discusses responses observed in transplant-eligible patients with multiple myeloma.

The FDA has granted a regenerative medicine advanced therapy designation to the allogeneic chimeric antigen receptor T-cell therapy ALLO-715 for the treatment of relapsed or refractory multiple myeloma,.

David Dingli, MD, PhD, discussed the case of a 51-year-old patients with transplant-eligible myeloma.

Rafael Fonseca, MD, reviews efficacy and safety data from the phase 3 MAIA trial and discusses their implications for clinical practice.

Rafael Fonseca, MD, discusses the role of monoclonal antibodies in the first-line setting in patients with newly diagnosed multiple myeloma.